AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
Story summaryAstraZeneca's stock jumped as much as 4% after Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials.
Read at CNBCOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.